Table 1 Patient and lesion characteristics
Patients (N = 194) | Value |
|---|---|
Age, years | 51 (23–83) |
Menopausal status | |
 Pre | 93 (47.9) |
 Post | 101 (52.1) |
Indication | |
 New cancer | 126 (64.9) |
 Screening/problem solving | 68 (35.1) |
Breast density | |
 Fatty | 5 (2.6) |
 Scattered fibroglandular | 47 (24.2) |
 Heterogeneously dense | 108 (55.7) |
 Dense | 34 (17.5) |
Background parenchymal enhancement | |
 Minimal | 58 (29.9) |
 Mild | 79 (40.7) |
 Moderate | 37 (19.1) |
 Marked | 20 (10.3) |
Lesions per patient | |
 1 lesion | 157 (80.9) |
 2 lesions | 30 (15.5) |
 3 lesions | 7 (3.6) |
Lesions (N = 238) | |
Largest diameter, cm | |
 < 1.0 cm | 98 (41.2) |
 1.0–1.9 cm | 71 (29.8) |
 2.0–3.9 cm | 38 (16.0) |
 ≥ 4.0 cm | 31 (13.0) |
Type | |
 Mass | 135 (56.7) |
 NMLE | 99 (41.6) |
 Focus | 4 (1.7) |
Delayed phase kinetics(most suspicious) | |
 Persistent | 6 (2.5) |
 Plateau | 34 (14.3) |
 Washout | 198 (83.2) |
BI-RADS | |
 4 | 218 (91.6) |
 5 | 20 (8.4) |
Histopathology | |
 Malignant | 95 (39.9) |
 Benign | 143 (60.1) |
Cancer subtype (n = 90*) | |
 Invasive | 73 (81.1) |
 DCIS | 17 (18.9) |
Benign subtype (n = 143) | |
 Fibroadenoma | 25 (17.5) |
 Fibrocystic changes | 21 (14.7) |
 Fibrosis | 14 (9.8) |
 Usual ductal hyperplasia | 12 (8.4) |
 Apocrine metaplasia | 11 (7.7) |
 Lobular neoplasia (LCIS, ALH) | 9 (6.3) |
 Papilloma | 9 (6.3) |
 Adenosis | 8 (5.6) |
 Pseudoangiomatous stromal hyperplasia | 6 (4.2) |
 Inflammation | 5 (3.5) |
 Atypical ductal hyperplasia | 4 (2.8) |
 Fibroadenomatoid change | 4 (2.8) |
 Normal breast tissue | 4 (2.8) |
 Other miscellaneous | 11 (7.7) |